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Prevalence of malaria infection in pregnant women 
compared with children for tracking malaria transmission in 
sub-Saharan Africa: a systematic review and meta-analysis
Anna M van Eijk, Jenny Hill, Abdisalan M Noor, Robert W Snow, Feiko O ter Kuile
Summary
Background In malarious areas, pregnant women are more likely to have detectable malaria than are their non-
pregnant peers, and the excess risk of infection varies with gravidity. Pregnant women attending antenatal clinic for 
their ﬁ rst visit are a potential pragmatic sentinel group to track the intensity of malaria transmission; however, the 
relation between malaria prevalence in children, a standard measure to estimate malaria endemicity, and pregnant 
women has never been compared.
Methods We obtained data on malaria prevalence in pregnancy from the Malaria in Pregnancy Library (January, 2015) 
and data for children (0–59 months) were obtained from recently published work on parasite prevalence in Africa and 
the Malaria in Pregnancy Library. We used random eﬀ ects meta-analysis to obtain a pooled prevalence ratio (PPR) of 
malaria in children versus pregnant women (during pregnancy, not at delivery) and by gravidity, and we used meta-
regression to assess factors aﬀ ecting the prevalence ratio.
Findings We  used data from 18 sources that included 57 data points. There was a strong linear relation between the 
prevalence of malaria infection in pregnant women and children (r=0·87, p<0·0001). Prevalence was higher in 
children when compared with all gravidae (PPR=1·44, 95% CI 1·29–1·62; I²=80%, 57 studies), and against 
multigravidae (1·94, 1·68–2·24; I²=80%, 7 studies), and marginally higher against primigravidae (1·16, 1·05–1·29; 
I²=48%, 8 studies). PPR was higher in areas of higher transmission.
Interpretation Malaria prevalence in pregnant women is strongly correlated with prevalence data in children obtained 
from household surveys, and could provide a pragmatic adjunct to survey strategies to track trends in malaria 
transmission in Africa.
Funding The Malaria in Pregnancy Consortium, which is funded through a grant from the Bill & Melinda Gates 
Foundation to the Liverpool School of Tropical Medicine, UK; US Centers for Disease Control and Prevention; and 
Wellcome Trust, UK.
Copyright van Eijk et al. Open Access article published under the terms of CC BY.
Introduction
In malaria transmission areas, pregnant women—in 
particular primigravidae—are known to be susceptible to 
malaria and to have higher prevalence and densities of 
parasitaemia than are non-pregnant women from the 
same population.1 The size of the excess risk varies with 
the age of the pregnant woman, reﬂ ecting cumulative 
exposure to malaria over a lifetime, and with parity, as a 
result of pregnancy-speciﬁ c immunity acquired after 
exposure to malaria in previous pregnancies. The 
consequences of malaria infection during pregnancy will 
depend on maternal malaria immune status; however, 
infections are associated with maternal anaemia and 
fetal growth retardation, and can result in acute illness, 
pregnancy loss or preterm delivery, and even maternal 
mortality.
The World Health Organization recommends use of 
insecticide-treated nets (ITNs) and intermittent 
preventive treatment in pregnancy (IPTp) with a dose of 
sulfadoxine-pyrimethamine at every scheduled antenatal 
care visit for the prevention of malaria in pregnancy in 
areas with moderate-to-high malaria transmission.2-4 
However, because of rising parasite resistance to 
sulfadoxine-pyrimethamine and decreasing malaria 
transmission in some regions, alternative strategies for 
IPTp are now being assessed, such as screening and 
treatment strategies in pregnancy. This approach consists 
of the use of rapid diagnostic tests to screen women for 
malaria at the ﬁ rst or each antenatal visit and treatment 
of positive women with artemisinin combination 
therapies.5
Data for malaria prevalence in children obtained from 
household surveys, such as malaria indicator surveys or 
school-based surveys, are used to measure transmission 
intensity and success of malaria control activities in a 
region.6,7 Household surveys are logistically demanding 
and expensive. School surveys, by contrast, are cheaper 
to do and often include larger sampled populations;8 
however, neither approach provides a simple routine 
real-time measure of malaria in the community. Pregnant 
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women attending antenatal care are a potential alternative 
source of data for malaria prevalence.
A systematic review9 showed that antenatal clinic 
attendance in pregnant women in most countries in sub-
Saharan Africa is high, with at least 75% of pregnant 
women attending one or more visits in 44 countries in 
2010, and at least 90% of pregnant women doing so in 
21 countries. That pregnant women are easily accessible 
for contact at antenatal clinics especially for ﬁ rst visits, 
makes them a potential surveillance population to track 
malaria transmission intensity. Because women at the ﬁ rst 
antenatal clinic visit have not yet received their ﬁ rst dose of 
sulfadoxine-pyrimethamine for IPTp, malaria infection 
prevalence at this ﬁ rst visit is likely to be an indicator of 
malaria transmission intensity in their community. 
Information on the prevalence of malaria infection at the 
antenatal booking appointment may become more widely 
available if screen and treat approaches for malaria control 
in pregnant women were to be adopted in areas with low 
or reduced transmission in Africa.5
In this meta-analysis, we investigate the relation 
between malaria infection prevalence in pregnant 
women and the more standard reference population of 
children from the same community. We use assembled 
data from across Africa published since 1983 to assess 
how any correlation might be modiﬁ ed by gravidity and 
malaria transmission intensity.10
Methods
Search strategy and selection criteria
We obtained data on the prevalence of malaria infection 
in pregnant women from the Malaria in Pregnancy 
Library.11 This library is a comprehensive bibliographic 
database created by the Malaria in Pregnancy Consortium 
that is updated every 4 months with a standardised 
protocol to search more than 40 sources, including 
PubMed, Web of Knowledge, and Google Scholar.12 We 
used data up to January, 2015, without language 
restriction.12
Inclusion criteria were: studies in sub-Saharan Africa, 
based in either the community or antenatal clinics, that 
screened pregnant women for malaria parasitaemia by 
microscopy or rapid diagnostic test, irrespective of the 
presence of symptoms. We excluded studies that selected 
only women with a history of fever or malaria, and 
studies that diagnosed malaria at delivery, so that the 
data for pregnant women would be comparable with 
those for women attending antenatal clinic. There was 
no time limit for inclusion and we did not restrict study 
selection to those with ﬁ rst antenatal visit data.
We undertook a systematic evaluation of studies in 
pregnant women and extracted data including study 
location, year of study, study population, inclusion and 
exclusion criteria used, use of malaria prevention 
strategies (ITNs, IPTp, or prophylaxis), type of malaria 
diagnostic test used, and test results. Where suﬃ  cient 
information was available, data were extracted by 
gravidity group, study site, and malaria season. Where 
needed, and if possible, we contacted authors of the 
included studies for additional information.
Data on the prevalence of malaria infection in pregnant 
women were then selected on the basis of the availability 
of the same prevalence data in children aged 0–59 months 
collected during the same study period and in the same 
locality as the data in pregnant women. The 
contemporaneous prevalence data in children and 
pregnant women were either extracted from studies 
reported in the Malaria in Pregnancy Library that also 
reported data in children, or obtained from surveys that 
collected data on pregnant women and children 
simultaneously. We identiﬁ ed these data from the large 
database of over 28 483 temporally and spatially unique 
surveys of malaria infection undertaken across Africa 
since 1980 and described elsewhere,6 and from nationally 
representative household surveys, such as Demographic 
and Health Surveys, Multiple Indicator Cluster Surveys, 
and Malaria Indicator Surveys.13–15 An overview of the 
methods used in these surveys has been reported 
previously.9,16 The information we extracted from the 
child records included study population, inclusion and 
exclusion criteria used, use of ITNs, type of malaria 
diagnostic test used, and test results.
We assessed the quality of studies after considering 
source population, participant selection, appropriate 
tests, characteristics reporting, and completeness of 
outcome data. Quality was classiﬁ ed as low-to-moderate 
or good. Further details of the methods used to assess 
quality are included in the appendix.
Statistical analysis
Meta-analyses were conducted using Stata (version 13, 
StataCorp LP, College Station, TX, USA) using the metan 
command with input of numerators and denominators for 
pregnant women and children and the “rr” option to pool 
the prevalence. We expressed diﬀ erences between 
prevalence estimates in pregnant women and children as 
See Online for appendix
Figure 1: Flow diagram for the literature search
7011 records in the malaria in pregnancy 
 database January, 2015
Identification
Screening
Eligibility
Included
631 records identiﬁed with point prevalence 
 information on malaria in pregnancy
631 records assessed for eligibility
57 sub-studies in 18 included records 
7011 records screened
314 records excluded because malaria 
 measurement was at delivery 
299 records excluded because there was 
 no match with children 0–59 months 
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pooled prevalence ratio (PPR) obtained by meta-analyses 
using DerSimonian and Laird random-eﬀ ects models.17 
We used random eﬀ ects models because of the wide 
heterogeneity in study design and to minimise the eﬀ ect of 
study size.18 The extent of heterogeneity was measured 
using the I², a measure of the proportion of total variability 
explained by heterogeneity rather than chance expressed 
as a percentage,19 with 0–40% representing no or little 
heterogeneity, 30–60% moderate heterogeneity, 50–90% 
substantial heterogeneity, and 75–100% considerable 
heterogeneity.20 To explore determinants of the relation 
between the prevalence in pregnant women versus 
children, we examined sources of heterogeneity across 
studies of the PPR estimates using random-eﬀ ects meta-
regression.21 Regression coeﬃ  cients were presented as 
odds ratios (ORs) and their corresponding 95% CIs. We 
estimated between-study variance (τ²) using the algorithm 
of residual (restricted) maximum likelihood, and calculated 
p values, and 95% CIs for coeﬃ  cients using the modi-
ﬁ cation by Knapp and Hartung.22 For the meta-regression, 
study-level predictors were considered for inclusion in the 
initial models if the p value for the univariate association 
of that variable with the endpoint was <0·2.
We considered the eﬀ ect of the following predictors: 
gravidity, study period, location of recruitment for 
pregnant women (community or antenatal clinic), 
coverage of antimalarial prevention (chemoprophylaxis 
or IPTp) in pregnant women, type of diagnostic test, 
malaria transmission intensity, as deﬁ ned by the average 
malaria prevalence among children and pregnant women 
(as a continuous variable and stratiﬁ ed as <5%, 5–40%, 
>40%),23,24 and ITN coverage. Because there is a high 
correlation between ITN use in pregnant women and 
children (appendix), we used data for coverage in 
children to represent both groups.
HIV infection is known to increase the risk of malaria 
in pregnancy;25 however, unfortunately none of the 
included studies had a systematic assessment of maternal 
HIV status. As an approximation of maternal HIV status, 
we used the information from the prevalence of HIV in 
women aged 15–49 years in the same study, or data from 
a Demographic and Health Survey closest to the study 
date, or data from other sources by country in all people 
aged 15–49 years (appendix).
We did a sensitivity analysis to explore the potential 
eﬀ ect of the type of study included (regional survey 
versus observational study) and of study quality on the 
primary outcome by comparing the results of (sub)
national surveys with local studies, or results from low-
to-moderate studies with those from good quality studies.
Role of the funding source
The funding institution had no role in the design and 
development, data extraction, analysis and interpretation 
of the data, or preparation, review, or approval of the 
paper. AMvE had full access to all data and had ﬁ nal 
responsibility for the decision to submit for publication.
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Results
Of 7011 records screened, we identiﬁ ed 18 data sources 
(13 national or subnational surveys and ﬁ ve local studies)26–50 
with information in children that could be matched with 
studies in pregnant women, resulting in 57 substudies after 
stratiﬁ cation of information by location and study period 
(ﬁ gure 1). Table 1 and the appendix show study 
characteristics and the results of the quality assessment.
Studies took place between 1983 and 2012; one study 
recruited participants from an antenatal clinic and all 
others were from the community.38 Five sources used 
rapid diagnostic malaria tests. There was no uniform 
reporting method on use of malaria prophylaxis or IPTp 
in pregnant women; four sources reported case 
management, and for surveys where IPTp was reported, 
the use varied from 3% to 94% for at least one dose of 
sulfadoxine-pyrimethamine. The estimated HIV 
prevalence in women ranged from 1% to 26%; prevalence 
was less than 10% in two-thirds of sources (12 of 18). 
Seven of 18 sources were considered good quality; the 
least commonly reported criterion was the number of 
women and children who were missing a blood test 
result.
There was a strong correlation between the pre-
valence of malaria infection in children aged 
0–59 months and pregnant women (Pearson correlation 
coeﬃ  cient 0·87, p<0·0001, ﬁ gure 2), with the average 
prevalence in children higher than that in pregnant 
women (PPR 1·44, 95% CI 1·29–1·62, ﬁ gure 3), but 
with considerable heterogeneity between studies 
(I²=80%, 95% CI 75–84).
Results of meta-regression identiﬁ ed the following 
eﬀ ect modiﬁ ers of the overall PPR (table 2): higher PPR 
when the average infection prevalence was higher, and 
children’s age group, with a higher PPR when comparing 
children aged 6–59 months with pregnant women than 
when comparing children aged 0–59 months with 
pregnant women (p=0·017 for the eﬀ ect of age in the 
multivariate model).
The type of malaria test used did not have an eﬀ ect on 
PPR (rapid diagnostic tests only 1·41, 95% CI 1·18–1·69; 
microscopy only 1·47, 1·27–1·71; p=0·535 for the eﬀ ect 
of diagnostic test in the univariate model).
We explored the relation further for malaria 
transmission; in subgroup analysis, there was less 
heterogeneity in areas with a prevalence below 5% (I² 42%, 
0–70, table 2) but in areas with a higher prevalence I² was 
more than 80%. The graph of the log prevalence ratio 
(ﬁ gure 4) showed a more consistent pattern in the areas of 
high malaria prevalence, but even in areas with a 
prevalence of over 40%, heterogeneity was high.
A sensitivity analysis in all studies showed that PPRs 
were lower when analysis was restricted to low-to-
moderate quality studies (1·34, 95% CI 1·17–1·54) than 
when analysis included only higher quality studies 
(PPR 1·76, 95% CI 1·39–2·24, p=0·086) but this 
diﬀ erence in eﬀ ect was not signiﬁ cant in the multivariate 
model (p=0·121). PPR for pregnant women versus 
children also diﬀ ered slightly when restricting the 
analysis to local studies only (PPR 1·67, 95% CI 1·46–1·92 
compared with subnational or national surveys only, 
1·39, 1·21–1·86), but this was not signiﬁ cant (meta-
regression: p=0·362).
Figure 2: Scatter plots for malaria prevalence in all pregnant women, primigravidae, and multigravidae 
versus children 0–59 months, sub-Saharan Africa, 1983–2012
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A small number of studies provided enough detail to 
allow analysis by gravidity group.26,28,37-39,40,49,51 The PPR of 
children versus primigravidae was much lower (1·16, 
95% CI 1·05–1·29, 8 studies, I² 48%, ﬁ gure 5) than the 
overall PPR, whereas the diﬀ erence between children 
and multigravidae was higher (PPR 1·94, 1·68–2·24, 
7 studies, I² 80%, ﬁ gure 5). The correlation coeﬃ  cients 
were 0·95 (p <0·0001) and 0·93 (p=0·003, ﬁ gure 2), for 
the comparison in primigravidae and multigravidae, 
respectively. All studies were conducted in areas of 
Figure 3: Forest plot of prevalence ratios for malaria in children (0–59 months) versus pregnant women, sub–Saharan Africa, 1983–2012
Mx=microscopy. RDT=rapid diagnostic malaria test. SNNPR=Southern Nations, Nationalities and People’s Region. Dotted line shows the pooled prevalence ratio. 
Studies are listed in ascending order of prevalence of malaria in children.
Malaria
test
Country and region Median
year
Ethiopia Oromia35
Sudan White Nile48
The Gambia Upper River43
The Gambia North Bank West43
The Gambia North Bank East43
Sudan North Kordofan48
The Gambia Central River43
Rwanda46
Sudan Kassala48
Rwanda45
Namibia42
Sudan Sinnar and South Gezira48
Ethiopia Amhara35
Côte d’Ivoire Abidjan28
Angola Luanda26
Sudan Gedaref48
Ethiopia SNNPR35
South Sudan Upper Nile47
Ethiopia Gilgel Gibe29
Sudan Darfur and Bahr el Gazal48
Ethiopia Gilgel Gibe29
Mozambique South Highland37
Equatorial Guinea Bioko33
Equatorial Guinea Bioko33
Sudan South and West Kordofan48
Côte d’Ivoire North28
South Sudan Bahr El Gabal47
Angola Meso-endemic unstable26
Côte d’Ivoire South28
Côte d’Ivoire Centre28
Mozambique South Coastal37
Mozambique Centre Highland37
Angola Meso-endemic stable26
Côte d’Ivoire West28
Mozambique South40
Angola hyperendemic26
Mozambique Centre Plateau37
Mozambique North Highland37
Mozambique North Centre Highland37
Mozambique Centre Coastal37
Mali Bandiagara31,32
Mozambique North40
Mozambique South Plateau37
Mozambique North Plateau37
Mozambique Central40
South Sudan Equatorial47
Mozambique North Coastal37
Equatorial Guinea Mainland44
Tanzania Tanga38
Mozambique North Centre Coast37
Equatorial Guinea Mainland44
Kenya Gem49
Equatorial Guinea Mainland44
Mali Bandiagara31,32
Equatorial Guinea Mainland44
Equatorial Guinea Mainland44
Kenya Asembo39
Overall (I2=80%, 95% CI 75–84%, p<0·0001)
Mx
Mx
RDT
RDT
RDT
Mx
RDT
Mx
Mx
Mx
RDT
Mx
Mx
Mx
RDT
Mx
Mx
RDT
Mx
Mx
Mx
Mx
RDT
RDT
Mx
Mx
RDT
RDT
Mx
Mx
Mx
Mx
RDT
Mx
Mx
RDT
Mx
Mx
Mx
Mx
Mx
Mx
Mx
Mx
Mx
RDT
Mx
RDT
Mx
Mx
RDT
Mx
RDT
Mx
RDT
RDT
Mx
2007
2005
2008
2008
2008
2005
2008
2010
2005
2008
2009
2005
2007
2012
2007
2005
2007
2009
2009
2005
2009
2003
2009
2008
2005
2012
2009
2007
2012
2012
2003
2003
2007
2012
2007
2007
2003
2003
2003
2003
1994
2007
2003
2003
2007
2009
2003
2011
1983
2003
2009
2003
2008
1993
2007
2010
1994
 1/225
 1/241
 5/991
 2/342
 3/367
 2/189
 7/546
 57/4046
 4/239
 121/4662
 53/1977
 9/227
 28/643
 21/457
 38/682
 9/132
 11/142
 85/1093
 100/1203
 54/611
 127/1207
 28/253
 333/2662
 336/2383
 59/384
 78/508
 140/777
 79/421
 117/612
 232/1125
 118/537
 238/953
 223/880
 125/480
 277/1000
 148/514
 209/673
 222/617
 298/805
 215/580
 490/1162
 729/1720
 169/393
 264/599
 496/1108
 558/1123
 291/581
 836/1602
 166/297
 369/648
 1006/1717
 700/1162
 842/1334
 786/1204
 1197/1770
 1165/1664
 256/328
 0·4
 0·4
 0·5
 0·5
 0·9
 1·1
 1·2
 1·4
 1·7
 2·6
 2·7
 4·0
 4·4
 4·7
 5·5
 6·8
 7·7
 7·8
 8·3
 8·8
 10·5
 11·0
 12·5
 14·1
 15·4
 15·4
 18·0
 18·7
 19·0
 20·7
 22·0
 25·0
 25·3
 26·1
 27·7
 28·8
 31·0
 36·0
 37·0
 37·0
 42·2
 42·4
 43·0
 44·0
 44·8
 49·7
 50·0
 52·2
 55·9
 57·0
 58·6
 60·2
 63·1
 65·3
 67·6
 70·0
 78·0
 1/37
 0/38
 2/167
 0/69
 2/49
 0/30
 3/84
 2/486
 0/33
 6/642
 8/192
 2/38
 7/132
 7/67
 6/84
 2/45
 1/40
 12/124
 8/111
 1/58
 8/131
 34/150
 27/197
 36/284
 8/78
 2/64
 12/182
 7/48
 8/109
 8/139
 52/163
 51/195
 22/135
 4/72
 15/90
 14/78
 43/144
 10/45
 54/121
 55/173
 19/124
 36/210
 37/157
 33/70
 22/159
 20/129
 28/88
 52/177
 82/196
 75/225
 31/122
 241/672
 26/64
 47/111
 109/258
 55/120
 504/1199
 2·7
 0·0
 1·1
 0·0
 3·8
 0·0
 3·1
 0·5
 0·0
 0·9
 4·2
 5·3
 5·3
 10·7
 6·9
 4·4
 2·5
 9·7
 7·2
 1·7
 6·1
 22·9
 13·5
 12·5
 10·3
 3·5
 6·7
 15·4
 7·6
 6·1
 32·1
 26·3
 16·0
 6·0
 16·7
 17·9
 30·2
 22·5
 44·5
 31·9
 15·3
 17·1
 23·4
 47·1
 13·8
 15·3
 31·6
 29·1
 41·8
 33·2
 25·4
 35·9
 40·6
 42·3
 42·3
 45·8
 42·0
0·16 (0·01–2·57)
0·48 (0·02–11·66)
0·42 (0·08–2·15)
1·02 (0·05–21·02)
0·20 (0·03–1·17)
0·82 (0·04–16·59)
0·36 (0·09–1·36)
3·42 (0·84–13·98)
1·27 (0·07–23·16)
2·78 (1·23–6·28)
0·64 (0·31–1·33)
0·75 (0·17–3·35)
0·82 (0·37–1·84)
0·44 (0·19–0·99)
0·78 (0·34–1·79)
1·53 (0·34–6·84)
3·10 (0·41–23·28)
0·80 (0·45–1·43)
1·15 (0·58–2·31)
5·13 (0·72–36·38)
1·72 (0·86–3·44)
0·49 (0·31–0·77)
0·91 (0·63–1·31)
1·11 (0·81–1·53)
1·50 (0·75–3·01)
4·91 (1·24–19·52)
2·73 (1·55–4·82)
1·29 (0·63–2·62)
2·60 (1·31–5·18)
3·58 (1·81–7·09)
0·69 (0·52–0·91)
0·95 (0·74–1·24)
1·56 (1·04–2·32)
4·69 (1·79–12·29)
1·66 (1·04–2·67)
1·60 (0·98–2·63)
1·04 (0·79–1·37)
1·62 (0·93–2·83)
0·83 (0·67–1·03)
1·17 (0·91–1·49)
2·75 (1·81–4·19)
2·47 (1·83–3·35)
1·82 (1·35–2·47)
0·93 (0·72–1·22)
3·24 (2·18–4·79)
3·20 (2·13–4·82)
1·57 (1·15–2·16)
1·78 (1·41–2·24)
1·34 (1·10–1·62)
1·71 (1·40–2·08)
2·31 (1·70–3·13)
1·68 (1·50–1·88)
1·55 (1·15–2·10)
1·54 (1·24–1·92)
1·60 (1·38–1·85)
1·53 (1·25–1·86)
1·86 (1·70–2·03)
1·44 (1·29–1·62)
Higher prevalence in
pregnant women
Higher prevalence in
children
10·01 25
Pregnant women Prevalence ratio
(95% CI)
Children (0–59 m)
n/N Prevalence 
(%)
n/N Prevalence 
(%)
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moderate to high transmission and results of meta-
regression did not show a diﬀ erence in the PPR between 
children and primigravidae (p=0·992) or multigravidae 
(p=0·209) when malaria transmission level was taken in 
to account; however, the number of studies for this 
analysis was small (table 3 and appendix).
Number of 
surveys
Pooled prevalence 
ratio (95% CI)
I² (%) (95% CI) for 
subgroup analysis
Odds ratio meta-
regression (95% CI)
p value 
by level
τ² Variance 
explained 
(%)
p (overall)
No covariates 57 1·44 (1·29–1·62) 80 (75–84) 0·182
Place of recruitment of pregnant 
women
ANC 1 1·34 (1·10–1·62) 0·93 (0·36–2·39) 0·877 0·190 0·0 0·877
Community 56 1·44 (1·28–1·63) 80 (75–85) 1·00 (Reference)
Malaria test
RDT 19 1·41 (1·18–1·69) 71 (54–82) 0·91 (0·66–1·24) 0·535 0·192 0·0 0·535
Microscopy 38 1·47 (1·27–1·71) 83 (78–87) 1·00 (Reference)
Time period (year)
<2000 4 1·72 (1·38–2·15) 80 (47–92) 1·26 (0·77–2·07) 0·344 0·175 0·0 0·344
≥2000 53 1·40 (1·23–1·60) 80 (74–84) 1·00 (Reference)
Average malaria prevalence * as 
an indicator of transmission level
Continuous 57 ·· ·· 1·00 (0·99–1·02) 0·139 0·177 2·4 0·139
>40% 13 1·51 (1·33–1·72) 84 (73–90) 1·79 (1·03–3·10) 0·039 0·184 0·0 0·084
5–40% 31 1·53 (1·24–1·88) 83 (77–88) 1·79 (1·06–3·04) 0·030
<5% 13 0·82 (0·47–1·40) 42 (0–70) 1·00 (Reference)
Antimalarial regimen during 
pregnancy†
None 18 1·17 (0·94–1·46) 89 (84–92) 1·00 (Reference) 0·154 15·5 0·106
IPTp 29 1·64 (1·41–1·91) 75 (64–82) 1·38 (1·01–1·88) 0·042
Prophylaxis‡ 10 1·61 (1·27–2·04) 34 (0–68) 1·38 (0·85–2·25) 0·188
ITN use during pregnancy
No ITN information 16 1·27 (1·07–1·51) 90 (86–93) 1·00 (Reference) 0·176 3·0 0·357
ITN use < 25% 22 1·57 (1·31–1·88) 65 (45–78) 1·18 (0·84–1·68) 0·332
ITN use ≥25% 19 1·64 (1·20–2·23) 72 (55–82) 1·29 (0·89–1·88) 0·173
Age deﬁ nition of child group
0–59 months 31 1·25 (1·07–1·47) 84 (78–88) 1·00 (Reference) 0·156 14·1 0·111
6–59 months 21 1·67 (1·29–2·18) 73 (58–82) 1·36 (0·98–1·87) 0·063
12–59 months 5 1·68 (1·49–1·90) 34 (0–75) 1·38 (0·89–2·14) 0·152
Estimate of maternal HIV 
infection†
Continuous 57 ·· ·· 0·98 (0·96–1·01) 0·139 0·179 1·6 0·139
>9% 16 1·40 (1·19–1·65) 89 (83–92) 0·94 (0·69–1·28) 0·676 0·187 0·0 0·676
≤ 9% 41 1·47 (1·24–1·75) 74 (65–81) 1·00 (Reference)
Multivariate analysis 0·149 17·9 0·025
Average malaria prevalence as an 
indicator of transmission level*
>40% 17 ·· ·· 2·03 (1·12–3·66) 0·020
5–40% 26 ·· ·· 1·97 (1·17–3·31) 0·012
<5% 14 ·· ·· 1·00 (Reference)
Age deﬁ nition of child group
0–59 months 31 ·· ·· 1·00 (Reference)
6–59 months 21 ·· ·· 1·49 (1·08–2·07) 0·017
12–59 months 5 ·· ·· 1·30 (0·81–2·11) 0·270
ANC=antenatal clinic. RDT=rapid diagnostic test. IPTp=intermittent preventive treatment in pregnancy. ITN= insecticide treated nets. *Average malaria prevalence in children 
and pregnant women. †Not signiﬁ cant in multivariate analysis. ‡Any dose for any time period of prophylaxis, not IPTp.
 Table 2: Meta-regression of factors that might aﬀ ect the prevalence ratio for malaria in children 0–59 months versus pregnant women in sub-Saharan 
Africa, 1983–2012
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Discussion
In this meta-analysis we compared the prevalence of 
malaria infection, as detected by microscopy or rapid 
diagnostic malaria tests, in pregnant women with the 
prevalence in children in the same study in the same 
calendar period and in the same location or region. We 
showed that the prevalence of malaria infection in 
pregnant women is lower than that in children aged 
0–59 months from the same population, although 
prevalence estimates in both groups were closely 
correlated, with a strong linear relation (r=0·87) across 
the endemicity spectrum.
The diﬀ erence in prevalence between children and 
pregnant women was smaller when the pregnant women 
were primigravidae and also in areas of low malaria 
transmission. Our ﬁ ndings suggest that changes in 
malaria infection prevalence in pregnant women 
attending routine antenatal care may be considered as an 
alternative indicator to track temporal and spatial trends 
in malaria transmission intensity.
Antenatal clinic populations are a convenient and easy-
to-access group for real-time malaria infection 
surveillance because most women attend antenatal clinic 
at least once during pregnancy, even in some hard-to-
reach rural areas. Women attend scheduled visits with a 
focus on preventive health strategies, prompt 
Figure 4: Bubble plot with ﬁ tted meta-regression line of the log prevalence ratio: child-maternal malaria 
prevalence and average malaria prevalence, sub-Saharan Africa, 1983–2012
Circles are sized according to precision of each estimate with larger bubbles for more precise estimates. Average 
malaria prevalence is the average of malaria prevalence in children and pregnant women.
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Figure 5: Forest plot of prevalence ratio of malaria in children aged 0–59 months versus primigravidae or multigravidae, sub-Saharan Africa, 1983–2012
Studies are listed in ascending order of prevalence of malaria in children.
Pregnant women Prevalence ratio
(95% CI)
Children (0–59 m)YearCountry 
and region
n/N Prevalence 
(%)
Côte d’Ivoire
Angola
Mozambique
The Gambia
Mozambique
Tanzania Tanga
Kenya Gem
Kenya Asembo
Overall (I2=48%, 95% CI 0–77%, p=0·060)
2012
2007
2007
1991
2003
1983
2003
1994
 573/3184
 487/2496
 1474/3829
 695/1465
 3335/6641
 166/297
 700/1162
 256/324
 12/93
 19/91
 22/72
 100/306
 114/266
 26/42
 46/88
 152/216
18·0
19·5
38·5
47·4
50·2
55·9
60·2
78·0
12·9
20·9
30·2
32·8
42·9
61·9
52·3
70·4
1·39 (0·82–2·38)
0·93 (0·62–1·40)
1·26 (0·89–1·79)
1·45 (1·22–1·71)
1·17 (1·02–1·35)
0·90 (0·70–1·17)
1·15 (0·94–1·41)
1·11 (1·00–1·23)
1·16 (1·05–1·29)
Côte d’Ivoire
Angola
Mozambique
Mozambique
Tanzania Tanga
Kenya Gem
Kenya Asembo
Overall (I2=80%, 95% CI 58–90%, p<0·001)
2012
2007
2007
2003
1983
2003
1994
 573/3184
 487/2496
 1474/3829
 3335/6641
 166/297
 700/1162
 256/324
 18/341
 19/91
 22/72
 100/306
 114/266
 46/88
 152/216
18·0
19·5
38·5
50·2
55·9
60·2
78·0
   5·3
11·6
15·6
30·1
36·4
33·3
35·6
3·41 (2·16–5·38)
1·68 (1·19–2·38)
2·50 (1·82–3·43)
1·67 (1·53–1·82)
1·54 (1·22–1·94)
1·81 (1·60–2·05)
2·19 (1·98–2·43)
1·94 (1·68–2·24)
n/N Prevalence 
(%)
10·5 6
Higher prevalence in
pregnant women
Higher prevalence in
children
10·5 6
A Primigravidae
B Multigravidae
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identiﬁ cation and treatment of illness or conditions, and 
birth planning. The patterns of malaria prevalence at 
antenatal booking (that is, before women have received 
any intervention) may, thus, reﬂ ect transmission 
intensity in their communities.
An advantage of using antenatal clinic data to assess 
trends in malaria transmission is that in many countries 
pregnant women are routinely screened for HIV, syphilis, 
and anaemia at their ﬁ rst antenatal booking visit and the 
addition of testing for malaria would not require any 
additional sampling. The large diﬀ erence in malaria 
prevalence between primigravidae and multigravidae 
suggest that gravidity would need to be taken into 
account.
That the risk of malaria in pregnant women is lower 
than that in children in areas of moderate-to-high 
transmission is not surprising. Parasites can sequester in 
the placenta, avoiding detection by diagnostic tests, and 
the concomitant peripheral parasite prevalence can be 
lower than that in the placenta. A meta-analysis by 
Kattenberg and colleagues52 reported a sensitivity of 
peripheral maternal blood microscopy of 72% (95% CI 
62–80) for detection of placental malaria, so if all 
placental malaria infections had been detected in the 
peripheral blood, in some regions the prevalence in 
pregnant women might have approached that recorded 
in children.
However, in areas of higher malaria transmission the 
prevalence gap between pregnant women and children 
increases and the lower detection level in the peripheral 
blood is not likely to explain the diﬀ erence. Previous 
studies and meta-analysis showed that pregnant women 
with acute malaria are consistently better at clearing 
parasites after antimalarial treatment with chloroquine 
or sulfadoxine-pyrimethamine than are children.10,53 This 
ﬁ nding probably reﬂ ects the higher level of acquired 
protective malarial immunity in pregnant women, 
especially multigravidae, in areas of high malaria 
endemicity and, thus, their ability to control and suppress 
parasite densities when infected relative to the immunity 
level in young children. Primigravidae generally do not 
have antibodies to placental-type parasites at the onset of 
pregnancy, but generate these during the course of 
pregnancy if exposed to malaria, and some have 
suggested using these antibody responses as sentinel 
markers for malaria transmission.54
In addition to gravidity, several other factors modiﬁ ed 
the relation between the population prevalence of malaria 
infection in pregnant women and children, including the 
age of the children used for comparison, with greater 
relative diﬀ erences with pregnant women in the 
6–59 months age group than 0–59 month old children. 
This likely reﬂ ects the lower risk of malaria in the ﬁ rst 
months of life compared with that later in infancy.55
Although there was a good correlation between malaria 
in children and pregnant women, the high heterogeneity 
across the malaria spectrum indicates that data in 
pregnant women may be more useful to assess trends 
than to use as an approximation of malaria transmission 
or to estimate malaria prevalence in other vulnerable 
groups. For example, for a malaria prevalence in pregnant 
women between 10% and 20% (12 data-points), the 
prevalence in children varied from 4·7% to 49·7%. The 
heterogeneity was less in areas of low transmission and 
in primigravidae.
There are important limitations to this type of 
secondary analysis that should be considered. First, these 
data might not be representative of sub-Saharan Africa 
because the number of studies with available data in both 
pregnant women and children at the same location and 
during the same time was small (18 sources). Second, 
most of the data for the comparison between children 
and pregnant women came from community-based 
surveys, and it is not yet clear whether these data are 
representative of the antenatal population, especially the 
potential target population for sentinel malaria 
surveillance––that is, those attending an antenatal clinic 
for their ﬁ rst booking visit. Most pregnant women in 
Africa have their ﬁ rst antenatal clinic visit before month 6 
of pregnancy (appendix), when the risk of malaria is 
high, compared with the third trimester (van Eijk, 
unpublished observation); use of malaria prevention 
such as chemoprophylaxis or IPTp in women attending 
for their ﬁ rst antenatal visit is unlikely, so that the 
prevalence of malaria among ﬁ rst antenatal clinic 
attendees may be closer to that of children than reﬂ ected 
in our analyses.
However, women who do not attend antenatal clinics 
may be at greater risk of malaria given that antenatal 
clinic attendance can be low in some rural populations, 
and in women with low socioeconomic status; both of 
these factors have been associated with an increased risk 
of malaria.9,16,56,57 Although this source of selection bias is 
likely to be small in malaria-endemic Africa where more 
than 90% women attend an antenatal clinic at least once,9 
in countries where this is not the case––that is, where 
more than 10% of women do not attend an antenatal 
clinic––population-based surveys may be needed to 
assess whether the risk of malaria infection in these 
women is diﬀ erent from that in women who do attend 
antenatal clinics.
Number of 
studies
Pooled prevalence 
ratio (95% CI)
I² (%) 
(95% CI)
Odds ratio meta-
regression
95% CI p
Primigravidae
>40% 5 1·16 (1·02–1·32) 66 (12–87) 0·99 0·68–1·46 0·992
5%–40% 3 1·16 (0·92–1·47) 0 (0–90) 1·00 Reference
Multigravidae
>40% 4 1·81 (1·54–2·12) 85 (63–94) 0·77 0·48–1·23 0·209
5%–40% 3 2·38 (1·63–3·48) 69 (0–91) 1·00 Reference
Table 3: Subgroup analysis of pooled prevalence ratio of malaria in children versus malaria in pregnant 
women by gravidity and by average malaria prevalence in children and pregnant women, sub-Saharan 
Africa, 1983–2012
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In settings where more than 10% of women do not 
attend ANC, the use of annealing methods should be 
considered that combine data from a relatively small 
random community survey sample with the convenience 
sample obtained from data that can be routinely collected 
in antenatal clinics, as has been done for HIV studies.58 
These hybrid prevalence estimators provide more 
accurate information than those available from using 
only data derived from antenatal clinics, and are more 
eﬃ  cient than when data are collected only through larger 
(and thus more expensive and only periodic) community-
based random survey samples such as in Demographic 
and Health Surveys or Malaria Indicator Surveys.58
Examples of countries with antenatal clinic attendance 
rates less than 90% in a malarious country include 
Nigeria (61% in 2013), Mali (74% in 2012–13), Angola 
(80% in 2006–07), Togo (73% in 2013), and the Central 
African Republic (68% in 2010) (appendix).
Another limitation of this analysis is that, although 
average malaria prevalence among children and pregnant 
women was used for the assessment of malaria 
endemicity, the 2–9 year age group is typically used for 
this.59 Further, the subnational surveys used a two-stage 
cluster sampling design and this might have had an 
eﬀ ect on the standard error around the prevalence 
estimate, but we could not take this eﬀ ect into account in 
our secondary analysis, which might have resulted in an 
overestimation of the precision of the eﬀ ect estimates.
In sensitivity analysis, the PPR from low-to-moderate 
quality studies was lower than the PPR of higher quality 
studies. This ﬁ nding might be partly explained by 
diﬀ erences in transmission intensity because the mean 
prevalence of malaria in children in low-to-moderate 
studies was about half that observed in the better quality 
studies (16% vs 31%, respectively). An alternative 
explanation might include diﬀ erent compositions of the 
study populations in low-to-moderate quality studies, 
with, for example, more primigravidae or women of 
young age. However, information available from the 
included studies was insuﬃ  cient to explore this theory 
further.
Although the biology and epidemiology of malaria and 
HIV diﬀ er substantially, lessons can be learned from the 
extensive experience with the use of antenatal data as a 
convenience sample for HIV-infection surveillance. For 
example, the use of hybrid prevalence estimators and the 
annealing of antenatal data with small random 
community samples to reduce bias.58 Overestimates have 
been reported when comparing estimates from antenatal 
clinics with community surveillance: suggested reasons 
included preferential antenatal attendance (for example, 
referral of people suspected of having HIV to certain 
clinics), the geographic under-representation of rural 
clinics (to obtain the sample size in the required period, 
high volume antenatal clinics are used which are more 
likely to be in urban areas), and cultural factors.60-63 
However, because of their consistent method and routine 
collection antenatal clinics are still the main source for 
trends in countries with generalised epidemics.63
Our meta-analysis found a strong linear relation 
between the prevalence of malaria infection in pregnant 
women and children from the same population. Routine 
information on the malaria infection status of pregnant 
women attending antenatal care might become 
increasingly available if countries switch from IPTp with 
sulfadoxine-pyrimethamine to “screen and treat” 
approaches. This switch could happen because of 
decreasing malaria transmission rates or increasing high-
grade resistance to sulfadoxine-pyrimethamine, the only 
antimalarial currently recommended for IPTp. Antenatal 
surveillance for malaria infection, especially during the 
ﬁ rst antenatal booking visit, should be explored as a 
pragmatic and sustainable method for the real-time 
monitoring of malaria trends.
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